PolyPid Ltd. (PYPD): Price and Financial Metrics


PolyPid Ltd. (PYPD): $8.23

-0.29 (-3.40%)

POWR Rating

Component Grades

Growth

S

Value

I

Momentum

G

Stability

N

Sentiment

U

Quality

P

PYPD Stock Price Chart Interactive Chart >

Price chart for PYPD

PYPD Price/Volume Stats

Current price $8.23 52-week high $16.50
Prev. close $8.52 52-week low $6.95
Day low $8.10 Volume 4,326
Day high $8.52 Avg. volume 48,999
50-day MA $8.07 Dividend yield N/A
200-day MA $9.53 Market Cap 140.29M

PolyPid Ltd. (PYPD) Company Bio


PolyPid Ltd. is a clinical stage biopharmaceutical company focusing on the development, manufacture, and commercialization of administered therapies to improve surgical outcomes. The company was founded by Noam Emanuel in 2008 and is headquartered in Petach Tikva, Israel.


PYPD Latest News Stream


Event/Time News Detail
Loading, please wait...

PYPD Latest Social Stream


Loading social stream, please wait...

View Full PYPD Social Stream

Latest PYPD News From Around the Web

Below are the latest news stories about PolyPid Ltd that investors may wish to consider to help them evaluate PYPD as an investment opportunity.

PolyPid to Present at Upcoming Cantor Fitzgerald Global Healthcare Conference

PETAH TIKVA, Israel, Sept. 20, 2021 (GLOBE NEWSWIRE) -- PolyPid Ltd. (Nasdaq: PYPD ), a phase 3 biopharmaceutical company focused on developing targeted, locally administered, and prolonged-release therapeutics using its proprietary PLEX technology, today announced its participation in the Cantor Fitzgerald Virtual Global Healthcare Conference on September 29 at 02:00 pm EDT.

Intrado Digital Media | September 20, 2021

PolyPid Shares Preclinical Data Of OncoPLEX Program For Brain Tumor

PolyPid Ltd (NASDAQ: PYPD ) has announced preclinical data in two key Glioblastoma Multiform (GBM) animal models of its OncoPLEX intra-tumoral cancer therapy program. OncoPLEX is designed to provide controlled local exposure to docetaxel, one of the most widely used chemotherapy agents. OncoPLEX induced strong inhibition of tumor growth and recurrence in a partially resected Full story available on Benzinga.com

Benzinga | September 13, 2021

PolyPid Announces Positive Preclinical Data of its Intra-tumoral OncoPLEX in Brain Cancer

PETAH TIKVA, Israel, Sept. 13, 2021 (GLOBE NEWSWIRE) -- PolyPid Ltd. (Nasdaq: PYPD), a phase 3 biopharmaceutical company focused on developing targeted, locally administered, and prolonged-release therapeutics using its proprietary PLEX technology, today announced positive preclinical data in two key Glioblastoma Multiform (GBM) animal models of its OncoPLEX intra-tumoral cancer therapy program.

Intrado Digital Media | September 13, 2021

PolyPid to Present at First World Association Against Infection in Orthopaedics and Trauma Congress

Virtual Presentation to be led by PolyPid Co-Founder and CSO on August 28, 2021 PETACH TIKVA, Israel, Aug. 17, 2021 (GLOBE NEWSWIRE) -- PolyPid Ltd. (Nasdaq: PYPD ), a late-stage biopharma focusing on developing targeted, locally administered and prolonged-release therapeutics to improve surgical

Investors Polypid | August 17, 2021

PolyPid Ltd. Reports Second Quarter 2021 Financial Results and Provides Corporate Update

Recruitment Progressing as Planned with Over 3 00 Patients Enrolled into Phase 3 SHIELD I Trial of D-PLEX 100 in Abdominal Surgery

Intrado Digital Media | August 11, 2021

Read More 'PYPD' Stories Here

PYPD Price Returns

1-mo -4.41%
3-mo -13.37%
6-mo -12.91%
1-year -34.68%
3-year N/A
5-year N/A
YTD -16.87%
2020 N/A
2019 N/A
2018 N/A
2017 N/A
2016 N/A

Get Free Updates

Join thousands of investors who get the latest news, insights and top rated picks from StockNews.com!


Page generated in 0.9572 seconds.